knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 17:59:38 - browse：21834

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Readout LOUD podcast: live from JPM 2024

WSS

Stigma and the return of syphilis

DeSantis can now import cheaper drugs. But will Biden get credit?

New England Journal of Medicine addresses racist history, slavery

Doulas covered by Medicaid under New York's new plan

Prosthetic arm enables patients to feel the objects they grip

As JPM 2024 winds down, some health tech firms project optimism

focus

knowledge

explore

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Heart attack and stroke risk calculators need revising

AI used to predict Covid

What does generative AI mean for health care? We asked experts

Heart disease and mental health: A look at cardiac psychology

As demand for Covid shots wanes, Moderna seeks its next success

David Sabatini, ex

After affirmative action ruling, medical educators look to 'holistic review'

Latest bird flu infection made farmworker sicker than earlier cases

explore

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Generative AI mines health records to identify patients’ social needs

Health and fitness trackers are measuring the wrong things

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Average age of first period drops to 11.9 years, study shows

knowledge

knowledge

hotspot

entertainment